Evaluation of tolerability of trifluridine/tipiracil combination tablet in patients with advanced/recurrent colorectal cancer

Abstract

Aim: This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age. Patients and Methods: Patients were divided into groups under the age of 75 years (n=62), and 75 years and over (n=17). The treatment period with TAS-102 tablet, reasons for discontinuation, adverse events (AEs), and overall survival (OS) were compared between the groups. Results: The incidence of AEs (including neutropenia, anemia, nausea, malaise, and anorexia) was similar for both groups and the treatment enforcement periods for different regimens were not statistically significant between the groups (p=0.207). No major differences were observed in the reasons for discontinuation, such as AEs or progressive disease, between the two groups. Conclusion: TAS-102 therapy for advanced/recurrent colorectal cancer is considered to be highly tolerable in patients 75 years and older. These findings are important for AE monitoring and guidance for patients taking TAS-102.